Interestingly, no reactivation of TB was observed in Rituximab (which does not eliminate IgA-specific B cells)-treated rheumatoid arthritis patients with LTBI suggesting that Mtb-specific IgA may be a critical effector antibody isotype in the lung [38]. Here, CD79A is linked to rheumatoid arthritis.